共识分子亚型 (CMS) 分类将结肠肿瘤分为四种亚型，有望作为预测生物标志物。然而，辅助化疗对 III 期患者每 CMS 无复发生存期 (RFS) 的影响仍未得到充分探讨。为此，我们从 2005 年至 2018 年间诊断的 MATCH 队列 (n = 575) 和 RadboudUMC (n = 276) 中选择了 III 期结肠癌 (CC) 患者。根据肿瘤位置对接受和未接受辅助化疗的患者进行匹配， T 阶段和 N 阶段 (n = 522)。 464 名患者可获得肿瘤材料，390 名患者成功提取 RNA 并进行 CMS 分型（单纯手术组：192 名，辅助化疗组：198 名）。在整个队列中，CMS4 与最差的预后相关（HR 1.55；p = .03）。多变量分析显示辅助化疗组在 CMS1、CMS2 和 CMS4 肿瘤中具有良好的 RFS（分别为 HR 0.19；p = .01，HR 0.27；p < .01，HR 0.19；p < .01），但无显着差异在 CMS3 内观察到治疗组之间的差异（HR 0.68；p = .51）。该非随​​机队列中的 CMS 亚型确定了预后不良的患者以及可能无法从辅助化疗中显着受益的患者。© 2024 作者。约翰·威利出版的《国际癌症杂志》

The consensus molecular subtype (CMS) classification divides colon tumors into four subtypes holding promise as a predictive biomarker. However, the effect of adjuvant chemotherapy on recurrence free survival (RFS) per CMS in stage III patients remains inadequately explored. With this intention, we selected stage III colon cancer (CC) patients from the MATCH cohort (n = 575) and RadboudUMC (n = 276) diagnosed between 2005 and 2018. Patients treated with and without adjuvant chemotherapy were matched based on tumor location, T- and N-stage (n = 522). Tumor material was available for 464 patients, with successful RNA extraction and CMS subtyping achieved in 390 patients (surgery alone group: 192, adjuvant chemotherapy group: 198). In the overall cohort, CMS4 was associated with poorest prognosis (HR 1.55; p = .03). Multivariate analysis revealed favorable RFS for the adjuvant chemotherapy group in CMS1, CMS2, and CMS4 tumors (HR 0.19; p = .01, HR 0.27; p < .01, HR 0.19; p < .01, respectively), while no significant difference between treatment groups was observed within CMS3 (HR 0.68; p = .51). CMS subtyping in this non-randomized cohort identified patients with poor prognosis and patients who may not benefit significantly from adjuvant chemotherapy.© 2024 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.